ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2162

Safety and Efficacy of Filgotinib: An Update from the DARWIN 3 Phase 2 Long-term Extension with a Maximum of 8.2 Years of Exposure

René Westhovens1, Rieke Alten2, Lorenzo Dagna3, Arthur Kavanaugh4, Kevin Withrop5, Jane Barry6, Robin Besuyen7, Claudio Corallo8, Dick de Vries9, Nicolas Martin10, Chris Watson6, Mark C. Genovese11, Alberto Spindler12, Mykola Stanislavchuk13, Maria Greenwald14 and Paul Emery15, 1Department of Rheumatology, KU Leuven, Skeletal Biology and Engineering Research Center, Leuven, Belgium, 2Department of Internal Medicine and Rheumatology, Schlosspark Klinik, University Medicine Berlin, Berlin, Germany, 3Department of Internal Medicine, IRCCS San Raffaele Hospital and Vita-Salute San Raffaele University, Milan, Italy, 4Division of Rheumatology, Allergy, and Immunology, University of California San Diego, La Jolla, CA, 5Oregon Health & Science University, Schools of Medicine and Public Health,, Portland, OR, 6Medical Affairs, Galapagos Biotech Ltd., Cambridge, United Kingdom, 7Clinical Development, Galapagos BV, Leiden, Netherlands, 8Medical Affairs, Galapagos Biopharma Italy S.R.L., Milan, Italy, 9Research and Development, Clinical Research, Galapagos BV, Leiden, Netherlands, 10Biostatistics, Galapagos NV, Mechelen, Belgium, 11Clinical Development, Gilead Sciences Inc., Foster City, CA, 12Rheumatology Section, Centro Medico Privado de Reumatologia, San Miguel de Tucuman, Argentina, 13Rheumatology, National Pirogov Memorial Medical University, Vinnytsia, Ukraine, 14Rheumatology, Desert Medical Advances, Palm Desert, CA, 15Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, and NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom

Meeting: ACR Convergence 2023

Keywords: clinical trial, Disease-Modifying Antirheumatic Drugs (Dmards), rheumatoid arthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 14, 2023

Title: (2141–2176) RA – Treatments Poster III

Session Type: Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: DARWIN 3 (NCT02065700) is a long-term extension (LTE) study assessing the safety and efficacy of filgotinib (FIL) in patients with rheumatoid arthritis (RA) and an inadequate response to methotrexate (MTX).1 In the DARWIN 1 (NCT01888874) and DARWIN 2 (NCT01894516) parent studies, patients received FIL in combination with MTX or FIL monotherapy, respectively. This analysis aimed to provide an update on the safety and efficacy of FIL 200 mg (FIL200) in patients with RA, with or without MTX, with a maximum of 8.2 years of exposure.

Methods: Patients completing the DARWIN 1 (FIL + MTX) and DARWIN 2 (FIL monotherapy) Phase 2 studies could enter DARWIN 3, receiving FIL200. The proportion of patients experiencing treatment-emergent adverse events (TEAEs) were reported using the safety analysis set, comprising data from both the parent and LTE studies. Efficacy was assessed from LTE baseline using the American College of Rheumatology (ACR) 20/50/70 improvement criteria and Disease Activity Score in 28 joints using C-reactive protein (DAS28-CRP), up to 264 weeks. Low disease activity and remission were defined as DAS28-CRP ≤ 3.2 and < 2.6, respectively.

Results: In total, 739 patients were enrolled in DARWIN 3. Mean (standard deviation; SD) FIL exposure was 4.89 (2.72) years in the FIL + MTX group and 4.78 (2.79) years in the FIL monotherapy group. In the FIL + MTX vs FIL monotherapy groups, TEAEs were reported for 90.9% and 92.1% of patients, respectively (Table). The most common TEAE was infection. In both treatment groups, 8 patients had a TEAE leading to death (1.6% and 3.3%, respectively). Exposure-adjusted incidence rates, censored at time of first event for major adverse cardiovascular event, venous thromboembolism, herpes zoster, infections, serious infections, nonmelanoma skin cancer (NMSC), malignancies excluding NMSC, gastrointestinal perforations and TEAEs leading to death, will be reported. Through 5 years, ACR20/50/70 responses were maintained in 86.3%/66.7%/50.7% of the FIL + MTX group and 90.8%/74.8%/51.4% of the FIL monotherapy group, respectively (observed data). DAS28-CRP low disease activity and remission rates (nonresponder imputation) at DARWIN 3 baseline were 46.1%/40.1% (FIL + MTX) and 29.6%/24.8% (FIL monotherapy) (Figure). At Week 264, the proportion of patients achieving low disease activity and remission were 34.0%/34.3% (FIL + MTX) and 27.0%/24.8% (FIL monotherapy).

Conclusion: With a maximum of 8.2 years of exposure in patients with RA, the FIL safety profile is similar between the background MTX and monotherapy treatment arms. Both arms show sustained efficacy over time.

Reference:
1. Kavanaugh A, et al. J Rheumatol 2021;48:1230–8

Supporting image 1

Table. TEAEs of interest

Supporting image 2

Figure. Proportion of patients achieving DAS28-CRP low disease activity and remission, from LTE baseline to Week 264 (nonresponder imputation analysis)


Disclosures: R. Westhovens: Celltrion, 2, 6, Galapagos, 2, 6, Gilead, 2, 6; R. Alten: AbbVie, 2, 6, Amgen, 2, 6, Biogen, 2, 6, BMS, 2, 6, Celltrion, 2, 6, Gilead, 2, 6, Janssen, 2, 6, Lilly, 2, 6, Medac, 2, 6, MSD, 2, 6, Mylan, 2, 6, Novartis, 2, 6, Pfizer, 2, 6, Roche, 2, 6, Sandoz, 2, 6, Sanofi-Genzyme, 2, 6, UCB, 2, 6, Viatris, 2, 6; L. Dagna: AbbVie, 2, AstraZeneca, 2, Biogen, 2, BMS, 2, 5, Boehringer Ingelheim, 2, Celltrion, 5, Eli Lilly, 2, Galapagos, 2, GSK, 1, Janssen, 2, Kiniksa Pharmaceuticals, 2, 5, Novartis, 2, 6, Pfizer, 2, 5, Sobi, 2, 5, 6; A. Kavanaugh: Amgen, 2, BMS, 2, Eli Lilly, 2, Novartis, 2, Pfizer, 2, UCB, 2; K. Withrop: AbbVie, 2, AstraZeneca, 2, BMS, 2, 5, Eli Lilly, 2, Galapagos, 2, Gilead, 2, GSK, 2, Novartis, 2, Pfizer, 2, 5, Regeneron, 2, Roche, 2, Sanofi, 2, UCB, 2; J. Barry: Galapagos, 3, 11; R. Besuyen: Galapagos, 3, 11; C. Corallo: Galapagos, 3, 11; D. de Vries: Galapagos, 3, 11; N. Martin: Galapagos, 7; C. Watson: Galapagos, 3, 11; M. Genovese: Gilead, 3, 11; A. Spindler: None; M. Stanislavchuk: Amgen, 5, AstraZeneca, 5, Celgene, 5, Eli Lilly, 5, Galapagos, 5, Gilead, 5, Human Genome, 5, Janssen, 5, MSD, 5, Nichi-Iko Pharmaceutical, 5, Pfizer, 5, Roche, 5; M. Greenwald: AbbVie, 5, Aclairs, 5, Eli Lilly, 5, Galapagos, 5, Janssen, 5, Nimbus, 5; P. Emery: Boehringer Ingelheim, 2, Eli Lilly, 2, Novartis, 2.

To cite this abstract in AMA style:

Westhovens R, Alten R, Dagna L, Kavanaugh A, Withrop K, Barry J, Besuyen R, Corallo C, de Vries D, Martin N, Watson C, Genovese M, Spindler A, Stanislavchuk M, Greenwald M, Emery P. Safety and Efficacy of Filgotinib: An Update from the DARWIN 3 Phase 2 Long-term Extension with a Maximum of 8.2 Years of Exposure [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/safety-and-efficacy-of-filgotinib-an-update-from-the-darwin-3-phase-2-long-term-extension-with-a-maximum-of-8-2-years-of-exposure/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/safety-and-efficacy-of-filgotinib-an-update-from-the-darwin-3-phase-2-long-term-extension-with-a-maximum-of-8-2-years-of-exposure/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology